


Convening + Uniting + Transforming

March webinar

A DANGEROUS DISRUPTION?

The Consequences of Delayed Care During COVID-19

Monday, March 22 4:00 to 5:00 p.m. ET





- O1 PCC announcements and introductions
- **O2** Moderated discussion among panelists
- 03 Audience Q&A



Today's speakers

PANELISTS

MODERATOR



DEANA MANASSARA BAPTISTE, PhD, MPH

Director of Cancer Screening Guideline Development, Americar Cancer Society



MARK TALLUTO

Vice President, Strategy and Analytics, BlueCross BlueShield Association



MAGDALA CHERY MBS, DO

Commonwealth Fund Fellow in Minority Health Policy, Harvard T.H. Chan School of Public Health



DIANE RITTENHOUSE, MD, MPH

Senior Fellow, Mathematica

Trends in Preventive Care Utilization during COVID

Key Findings

March, 2021




Blue Cross Blue Shield Association is an association of independent Blue Cross and Blue Shield companies.



After a large drop early in the pandemic, preventive care utilization had a strong recovery through October






Note: Preventive care procedures are identified based on CMS and AMA recommended preventive service procedure codes



There was a substantial drop in all preventive care services, particularly in cancer screenings and vaccines

Change in Preventive Care Utilization (# of claims per 100) through November - 2020 vs. 2019



■ 2019 Avg # of Claims per 100 Members


■ 2020 Avg # of Claims per 100 Members

Note: Preventive care procedures are identified based on CMS and AMA recommended preventive service procedure codes



Breast Cancer Screenings showed largest overall drop, while Cervical and Colorectal saw larger relative YoY declines


Change in Cancer Screening Utilization (# of claims per 100) through November - 2020 vs. 2019





Note: Preventive care procedures are identified based on CMS and AMA recommended preventive service procedure codes



Vaccination rates against Whooping Cough, Measles, and Polio have decreased by 26%, 26% and 16% respectively








Note: The beginning of COVID (March through May) and the back to school vaccine push (August) are where many vaccines have been missed in 2020

¹ DTaP vaccination protects against Diphtheria, Tetanus, and acellular Pertussis (Whooping Cough)

² MMR vaccination protects against Measles, Mumps, and Rubella



An estimated 9 million MMR/DTaP/Polio vaccination doses1 could be missed nationwide by children in 2020



¹ Missed vaccines are not equal to number of children who missed vaccines. An individual child could have missed more than one of these vaccines

^{*} DTaP vaccination protects against Diphtheria, Tetanus, and acellular Pertussis (Whooping Cough)

^{*} MMR vaccination protects against Measles, Mumps, and Rubella

²⁰¹⁹ Vaccination Rate Source: https://www.cdc.gov/mmwr/volumes/69/wr/mm6942a1.htm



Key Findings of Childhood Vaccinations

- Child vaccinations have dropped by as much as 26% for MMR, DTaP, and Polio Vaccines
- If the current downward trend in vaccinations is not made up, an estimated 9 million doses of the MMR, DTaP, and Polio vaccines could be missed in the US by the end of 2020
- Decreased vaccination rates put communities at higher risk of Measles and Whooping Cough outbreaks and could threaten current community protections against Polio






Delays in Cancer Screening and Diagnoses




ESTIMATES OF DELAYED/MISSED CANCER DIAGNOSES

Over 22 million screening tests for five common tumors may be disrupted, risking delayed or missed diagnoses for 80,000 patients




Changes in Newly Identified Cancers



Source: Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open. 2020;3(8):e2017267. doi:10.1001/jamanetworkopen.2020.17267



Model Estimates of Excess Breast and Colorectal Cancer Deaths




~5,500 excess breast cancer deaths by 2030

~4500 excess CRC cancer deaths by 2030



Source: Sharpless NE. COVID-19 and cancer. Science. 2020;368(6497):1290. doi:10.1126/science.abd3377

ACS Response to Resuming and Promoting Cancer Screening



SAFELY RESUMING AND PROMOTING CANCER SCREENING DURING THE COVID-19 PANDEMIC



Cancer prevention and early detection are central to the American Cancer Society's (ACS) mission to save lives, celebrate lives, and lead the fight for a world without cancer. Early detection of cancer through screening reduces mortality from cancers of the colon and restum, breast, uterine cervix, and lung [see <u>ACS screening guidelines</u>]. Cancer mortality has declined in recent decades in part due to progress in cancer screening technologies, awareness, research, and the general population's improved utake in screening services.

Yet, far too many individuals for whom screening is recommended remain unscreened, and this situation has been aggravated by the substantial decline in sance recenning resulting from the COVID-19 pandemia. At the onset of the pandemic, elective medical procedures, including cancer screening, were largely put on hold to prioritize urgent needs and reduce the risk of the spread of COVID-19 in health care settings. Early projections indicate that these extensive screening delays will lead not only to missed and advanced stage cancer disapresses. but also to a jets in cancer screening and survival across groups of people who have systemically experienced social or economic obstacles to screening and care.

In response to these challenges, ACS developed this report to summarize the current state and to provide guidance on how public health agencies, health care providers, and screening advocates across the nation can promote and deliver cancer screening appropriately, safely, and equitably during the COVID-19 pandemic.

A UNITED MESSAGE IN OUR RESPONSE TO THE DISRUPTIONS IN CANCER SCREENING

- Despite the challenges we face during the pandemic, cancer screening remains a public health priority, and we must provide the public with safe opportunities to prevent cancer or detect it early to improve patient outcomes.
- Screening disparities are already evident and, without deliberate focus, are likely to increase as a result of the COVID-19 pandemio. Efforts to promote screening and overcome barriers for populations with low screening prevalence must be at the forefront of our focus.
- Engaging patients in the resumption of cancer screening will require effective and trustworthy messaging.
- Implementation of process and policy changes are urgently needed to sustain access to primary care and return screening to pre-pandemic rates.



Screening refers to testing individuals who have no signs or symptoms of disease. It is critical to ensure that patients with rigur or symptoms associated with cancer undergo diagnostic evaluation as soon as possible, yet many people with symptoms — such as breast lumps, abnormal vaginal bleeding, blood in some importances, unexplained religit tous, fedgles, or anemia — continue to sooid medical care due to

It is important to reassure the public that aggressive infection control measures are being taken in health care facilities throughout the country to ensure that diagnostic procedures can be provided safely for patients with symptoms, and that these evaluations need not and should not be delayed

Cancer Screening During the COVID-19 Pandemic | October, 2020

Resources:

- https://www.acs4ccc.org/cancer-screening-and-care-during-the-covid-19-pandemic/
- https://www.acs4ccc.org/effectively-messaging-cancer-screening-during-the-covid-19-pandemic/





